Associations of SGLT-2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy.

Efstratios KoutroumpakisRushin PatelSumanth KhadkeAram BedrosianAshish KumarYixin KongBrendan ConnellJagriti UpadhyaySourbha S DaniAndrew W HahnChristopher J LogothetisSadeer Al-KindiJaved ButlerAnju NohriaSarju GanatraAnita Deswal

Published in: Research square (2024)

Use of SGLT2i for the treatment of T2DM among patients with prostate cancer on HT is associated with favorable cardiovascular, renal and all-cause mortality outcomes. This observation supports the hypothesis that a therapeutically relevant link exists between HT and cardiovascular disease in the context of prostate cancer.

Keyphrases

prostate cancer
radical prostatectomy
cardiovascular disease
type diabetes
glycemic control
adipose tissue
combination therapy
skeletal muscle
cardiovascular risk factors
smoking cessation